In Vivo Activity of WCK 4282 (High-Dose Cefepime/Tazobactam) against Serine-β-Lactamase-Producing Enterobacterales and Pseudomonas aeruginosa in the Neutropenic Murine Lung Infection Model-Reference-Cited by-同舟云学术

In Vivo Activity of WCK 4282 (High-Dose Cefepime/Tazobactam) against Serine-β-Lactamase-Producing Enterobacterales and Pseudomonas aeruginosa in the Neutropenic Murine Lung Infection Model

Published:2021-03-18 Issue:4 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Lasko Maxwell J.¹,Abdelraouf Kamilia¹^ORCID,Nicolau David P.¹²^ORCID

Affiliation:

1. Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA

2. Division of Infectious Diseases, Hartford Hospital, Hartford, Connecticut, USA

Abstract

WCK 4282 (cefepime 2 g-tazobactam 2 g) maximizes systemic exposure of tazobactam and restores cefepime activity against various extended-spectrum β-lactamase (ESBL)- and cephalosporinase-producing strains in vitro . We describe clinical WCK 4282 exposure efficacies against various serine β-lactamase-producing Enterobacterales and Pseudomonas aeruginosa isolates in a murine pneumonia model.

Funder

Wockhardt

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02193-20

Reference39 articles.

1. Microbial Etiology of Pneumonia: Epidemiology, Diagnosis and Resistance Patterns

2. The epidemiology of nonventilator hospital-acquired pneumonia in the United States

3. Adults Hospitalized With Pneumonia in the United States: Incidence, Epidemiology, and Mortality